Aviva Lev-Ari, PhD, RN
Founder, LPBI 1.0 & LPBI 2.0
2022
Picture date: February 6, 2022
UPDATED on 4/25/2022
TODAY, TEN years ago we on 4/25/2012 we published our 1st article
TODAY, 4/25/2022 we have 6,135 articles
TODAY, we have 2,115,903 Views at all time
http://pharmaceuticalintelligence.com
We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022
2022 Update from LPBI Group | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/
2021 – Present
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/aviva-lev-ari-phd-rn-founder-lpbi-group-1-0-2-0/
Director & Founder
2012 – 2020
Leaders in Pharmaceutical Business Intelligence (LPBI) Group
https://lnkd.in/eEyn69r
LinkedIn Profile
https://www.linkedin.com/today/author/avivalevari
2020
2020 VISION
Past Member of SRI Organon Toastmasters, 5/1985 – 9/1988: Aviva Lev-Ari, PhD, RN
LPBI Group’s Founder – A Profile for a Wikipedia Entry
Curator: Zach Day, with editorial comments by Prof. Marcus W. Feldman, Dr. Joel T. Shertok, PhD and Gail S. Thornton, PhD(c), MA
| 9/23/2020 | e-Readers | # Articles | Scientific Comments | Research Categories |
| LPBI Group | 1,828,635 | 5,923 | 7,448 | 718 |
| Aviva Lev-Ari, PhD, RN | 463,714 | 3,436 |
| 8/16/2020 | e-Readers | # Articles | Scientific Comments | Research Categories |
| LPBI Group | 1,805,762 | 5,898 | 7,442 | 715 |
| Aviva Lev-Ari, PhD, RN | 458,072 | 3,421 |
| 1/10/2020 | e-Readers | # Articles | Scientific Comments | Research Categories |
| LPBI Group | 1,706,087 | 5,728 | 7,375 | 694 |
| Aviva Lev-Ari, PhD, RN | 428,301 | 3,355 |
| 1/22/2019 | e-Readers | # Articles | Scientific Comments | Research Categories |
| LPBI Group | 1,563,240 | 5,469 | 7,308 | 666 |
| Aviva Lev-Ari, PhD, RN | 393,545 | 3,245 |
Founder’s articles published viewed more than 2,000 times
2019
Aviva Lev-Ari, PhD, RN serves as
- Administrator of the platform and its architect since 4/2012, the venture inception. # Views by eReaders of Administrator’s posts +430,000
- Is the Launcher of the Website PharmaceuticalIntelligence.com – 1,715,000 Views on 2/4/2020 since launch 4/2012
- Is the IP owner with agreements with each Expert, Author, Writer (EAW)
- Is the Editor-in-Chief of
- the Journal [PharmaceuticalIntelligence.com] and of
- the BioMed e-Series [https://pharmaceuticalintelligence.com/biomed-e-books/]
- Is the Co-Editor of several volumes in each series, except Series C: Cancer
- Is the Publisher of +3,300 of the 5,700 articles in the Journal
- Is the Developer of the Methodology of Curation for Pharmaceutics and Media top article 17,000 views, Several of Aviva’s articles fetch +10,000 views
- Is Developer of the Methodology of electronic Table of Contents (eTOCs) creation and was involved in the population of all eTOCs by Expert Editors that culled articles from the journal’s research categories to create ONE of a kind an eTOCs for each volume [except Series C: Cancer]
- Is Developer of the Methodology of Real Time Press Coverage of Top Biotech Conferences using social media and the ONE key stroke method for generation of the eProceedings.
- Is The Producer of 60 of the 70 Conference eProceedings in the venture’s Archive of Press Coverage of Biotech and Medical Conferences
- https://pharmaceuticalintelligence.com/press-coverage/part-two-list-of-biotech-conferences-2013-to-present/
- Lev-Ari is the creator of THREE intellectual property asset classes in Media & Healthcare (pharmaceutical, medicine, medical devices & diagnostics, bioinformatics). The three archives are ready for Text Analysis & Text Mining by AI, ML and NLP algorithms
- The three archives consist of the following IP assets:
-
LPBI Journal:
Open Access Online Scientific Journal PharmaceuticalIntelligence.com
- A collection of 5700 scientific articles +1.7 million eReaders, and
- The Journal Ontology of ~700 categories of Research
-
Sixteen volumes of Medical Books in Five specialties:
Series A: Cardiovascular – 6 volumes, BUNDLED BY AMAZON.COM INTO A SIX-VOLUME SERIES FOR $515
Series B: Genomics – 2 volumes
Series C: Cancer – 2 volumes
Series D: Immune system & Infectious Diseases – 3 volumes
Series E: Precision Medicine – 4 volumes
-
Biotech Conferences Press Coverage with Social Media:
- Lev-Ari is the Producer of Biotech & Medical Conference e-Proceedings:
- Is the developer of the methodology for Real Time Press coverage with social media,
- The archive of 70 eProceeding documents was produced at 70 Biotech and Medical Conferences covered in Real Time during attendance
- Each Conferences yielded on average 4 – 5 new curations in the Journal
- Is the presenter of the Twitter Analytics of LPBI Group’s social media coverage of each conference by @pharma_BI and by @AVIVA1950
For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers]
Is the creator of the 30 Collections of Tweets posted in real time at 60 of the 70 BioTech and Medical Conferences listed in
https://pharmaceuticalintelligence.com/press-coverage/
2019 was a year with a very good start. Key milestones include the following:
- Positioning Perspectives on LPBI’s Pipeline Map – An Outlook to the Future from the Present
Contributions by Aviva Lev-Ari, PhD, RN, Stephen J. Williams, PhD and Gail S. Thornton, MA, PhD(c)
- Since 2/6/2019 developing with the Team, 2019 VISTA – Exit Website
- 2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19 via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19
- By “Mentions” – Ranked #4: @pharma_BI and
- By “Tweets” – Ranked #2: @AVIVA1950
via NodeXL http://bit.ly/2KB6cPN
- By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI
- On 5/6/2019, was solicited by MIT Inclusive Innovation Challenge (MIT IIC) to register for 2019 applicant pool of entrepreneurs developing digital technologies for the workplace.
The IIC is the flagship program of the MIT Initiative on the Digital Economy, annually celebrating entrepreneurs who are using technology to create innovative solutions to global challenges. Global Winners will receive the award at the Global Grand Prize Gala at MIT. In the last three years, the IIC has awarded 100 organizations around the world. View past winners.
https://challenge.mitinclusiveinnovation.com/applications/2900/printable
- On 5/21/2019 – Mission Definition was Restated / Updated Profile of Leaders in Pharmaceutical Business Intelligence —–>>>>>> (LPBI) Group https://lnkd.in/desCCx7
- Expertise of our Team members includes functional areas of the e-Scientific Publishing segment https://lnkd.in/ejXnvUN
- Our IP is most valuable for several industrial sectors and economic segment as described https://lnkd.in/dNHYWGH
- We offer several Media Distribution Channels for Contents and Events as described https://lnkd.in/dnHVBKv
- We welcome partnerships and inter-organizational interfaces for collaboration purposes. We are seeking Joint Ventures, M&A and other structures to leverage our IP and the deep expertise of our Team
- On 7/31/2019 LPBI Group’s Executive Summary was crystalized by the Marketing Communications Specialist, Gail Thornton, based on content developed during the last two years as described in
https://pharmaceuticalintelligence.com/home-website-front-page/
- On 7/31/2019 Developed the conceptual framework for Biotech Information Infrastructure at a Country level as described in https://pharmaceuticalintelligence.com/vision/
These resources include:
- Pharmaceutical (BioMed eBooks),
- Media (e-Proceedings) and
- electronic Scientific Publishing (Journal)
- Gallery of ~5000 Images in Biological Sciences
- Muti-Authors authoring Platform, composition of methods, workflows and templates
- Human resources: Talent of experts in Medicine, BioMed, Life Sciences and Pharamcology
could be accessed on a National level (Country x,y,z) or at the EU level or another geography by
- All Life Science Incubators
- All Biotech Start ups
- All Life Sciences Departments in any Higher EducationInstitute
- All Medical Schools: Faculties using the content for curriculum development, Research Staff and Medical Students
- All High school students writing Honor Final thesis in Life Sciences
- All private individuals seeking knowledge in the Life Sciences & Medicine, Pharmaceutics and Health Care
- Private & Public interests can be served: the Biotech/Healthcare sectors, Education Sectors, and
- it can in parallel have a few business lines that are fully commercial for parties beyond Country x,y,z or the EU or another geography, i.e., Global and International NGOs such as Teva, IBM, GE Health, Siemens Healthineers, National’s HMOs can use the platform for Medical Doctors and Allied Health professionals continuing education using the contents of each of the three IP asset classes.
- On 8/6/2019 Published the Data Analysis for January 2019 – July 2019, revealing impressive results as described in
- December 6, 2019 – became Nominee for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional lifetime achievements reflect the excellence of a UC Berkeley education. Nominator: Prof. Sheila M. Puffer (UC, Berkeley, PhD’84).
https://awards.berkeley.edu/achievement-awards
The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.
- December 28, 2019 – volume #16 of the BioMed e-Series of 16-volumes on Amazon.com was published
Series B, Volume 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
https://www.amazon.com/dp/B08385KF87
2018 & 2019 Yearly Updates
Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
| 1/22/2019 | e-Readers | # Articles | Scientific Comments | Research Categories |
| LPBI Group | 1,563,240 | 5,469 | 7,308 | 666 |
| Aviva Lev-Ari, PhD, RN | 393,545 | 3,245 |
On 4/30/2019
| LPBI Group | 1,614,690 | 5,556 | 7,334 | 670 |
| Aviva Lev-Ari, PhD, RN | 404,843 | 3,268 |
On 9/10/2019
| LPBI Group | 1,661,050 | 5,678 | 7,361 | 687 |
| Aviva Lev-Ari, PhD, RN | 416,774 | 3,353 |
2018 was a year of a great increase in recognition for Dr. Lev-Ari, as the following events indicate:
- On 3/31/2018, Dr. Lev-Ari, PhD, RN was nominated for the 2018 Yidan Foundation Prize
Per request for supporting material, the following was submitted to the nominator, Prof. Marcus W. Feldman of Stanford University, Department of Biology.
Nomination for 2018 Yidan Prize, recognition in the field of medical education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN
Was prepared for publication in American Friends of the Hebrew University (AFHU), May 2018 Newsletter, Hebrew University’s HUJI Alumni Spotlight Section.
Aviva Lev-Ari’s profile was up on 5/3/2018 on AFHU website under the Alumni Spotlight at https://www.afhu.org/
- On 5/11/2018, Excerpts were Published in AFHU e-news.
https://us10.campaign-archive.com/?u=5c25136c60d4dfc4d3bb36eee&id=757c5c3aae&e=d09d2b8d72
https://www.afhu.org/2018/05/03/aviva-lev-ari/
- On 8/17/2018, Dr. Lev-Ari, PhD, RN was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board.
http://www.maacadsci.org
- On 10/15/2018, in meetings with professors at the University of California, Berkeley, a new initiative was launched for an Endowed Chair in the memory of the late Berkeley Professor of Geography, Allan Pred. It was Professor Pred’s advisee, Aviva Lev-Ari, PhD’83, who had the idea to launch this initiative in collaboration with Professor Michael Watts, who suggested that other advisees of Professor Pred who have pursued careers in industry become part of this project. Dr. Lev-Ari’s idea includes celebration of Professor Pred’s life’s work and writings by creating a new theater play using the curation methodology for writing a script based on his 20 published books. It is work-in-progress, with a kick-off meeting scheduled for 2/2019 in Boston.
- On 10/22/2018 the organization,.org, expressed interest in LPBI Group’s Patient Voices e-Book, Series E, Volume One: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures, located on Amazon.com since 10/16/2017. https://www.amazon.com/dp/B076HGB6MZ This organization inquired about development of a similar e-Book for the VOICES of Breast Cancer Patients. In response to this expressed interest, Dr. Lev-Ari has formulated Three Scenarios for the Scaling up Potential of LPBI Group’s BioMed e-Series: Lights on Intellectual Property Growth Capacity and the Business Potential of the Venture https://pharmaceuticalintelligence.com/2018/10/22/three-scenarios-for-the-scaling-up-potential-of-lpbi-groups-biomed-e-series-lights-on-intellectual-property-growth-capacity-and-the-business-potential-of-the-venture/
- On 12/7/2018, Dr. Lev-Ari was nominated for 2019 Berkeley Alumna of the Year Achievement Award
2019 Awardees
https://awards.berkeley.edu/achievement-awards
From: Danielle Wiskerson <dwiskerson@berkeley.edu>
Subject: 2019 Achievement Awards update
Date: February 7, 2019 at 9:27:30 PM EST
Dear Sheila:
On behalf of the Cal Alumni Association and the UC Berkeley Foundation Board of Trustees, we would like to thank you for your nomination of Aviva Lev-Ari for the Alumnus/a of the Year Award. Due to the high volume of qualified nominees, this year’s award process was difficult and Dr. Lev-Ari was not selected to be honored at this time.
We sincerely appreciate the effort you put into Dr. Lev-Ari’s nomination and thank you for participating in our award process. With support like yours, we will continue to acknowledge and award outstanding Berkeley alumni.
Sincerely,
Danielle
—
Danielle Wiskerson
Associate Director | External Relations
University of California, Berkeley | University Development and Alumni Relations
office: 510.642.4742 | cell: 510.812.0307
- In December 2018, Dr. Lev-Ari has published CVD Volumes 5 & 6, e-Book 14 and 15 in a 16-Volume BioMed e-Series
On Amazon.com since 12/23/2018
https://www.amazon.com/dp/B07MGSFDWR
On Amazon.com since 12/24/2018
https://www.amazon.com/dp/B07MKHDBHF
- @Amazon.com BUNDLED for $515 @pharma_BI a Six-volume series on #Cardiovascular #Diseases
https://www.amazon.com/dp/B07MVF34ZC/ref=sr_1_1?s=digital-text
https://lnkd.in/e6WkMgF
- Since 6/2013 to Present, e-Books 1 to 15 Volumes are published on @Amazon.com
#Genomics [Volume 1 & 2], #Cancer [Volume 1 & 2], #Metabolomics [Volume 1], #InfectiousDiseases [Volume 2], #Immunology [Volume 3], #Patient #Voices #Precision #Medicine [Volumes 1,2,3,4].
https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari
https://lnkd.in/ekWGNqA
- Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL. Author and Curator: Aviva Lev-Ari, PhD, RN
BIO
1985-2005, worked at Director Level with Start-ups and Fortune 100 companies making presentations at the CEO Board Room level. Is reinventing work so that it works for the digital global economy. Consults and speaks to large and small groups. Lead webinars for universities, corporations and associations, and generally stir up conversation and inquiry on industry trends.
- Startups:
- TimeØ Group
- Concept Five Technologies, Inc.
- MDSS, Inc.
- LPBI Group
- Top Tier Management Consulting: SRI International, Monitor Group;
- OEM: Amdahl Corporation;
- Top 6th System Integrator: Perot System Corporation;
- FFRDC: MITRE Corporation. In the
- Publishing industry: was Director of Research at McGraw-Hill/CTB.
- Northeastern University, Researcher on Cardiovascular Pharmaco-therapy at Bouve College of Health Sciences (Independent research guided by Professor of Pharmacology)
In 4/2012, have launched LPBI Group
Dr. Lev-Ari is an Executive-Entrepreneur with high energy and passion. Followed by 6800 Biotech professionals on LinkedIn and Group Manager of three Groups on LinkedIn:
(1) Pharmaceutical Intelligence,
(2) Cardiovascular Disease and
(3) Innovations in Israel.
Business expertise is at the intersection of
(a) electronic Scientific Media,
(b) Drug Discovery and
(c) Biotech Venture Funding.
BIO
-
Reflections on a Four-phase Career
Dr. Lev-Ari’s career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018, has the following phases:
- Phase 1: Research, 1973 – 1983
- Phase 2: Corporate Applied Research in the US, 1985 – 2005
- Phase 3: Career Reinvention in Health Care, 2005 – 2012
- Phase 4: Electronic Scientific Publishing, 4/2012 to present
-
Recollections of Years at UC, Berkeley, Part 1 and Part 2
- Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other professors and other peers
- Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83
-
Achievements in Three Academic Disciplines
3.1 Pioneering implementations of Analytics to Business decision making
Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76
3.2 Key Opinion Leader (KOL) in Pharmaceutical Business Intelligence
Digital KOL Parameters
Key Opinion Leader (KOL) – Aviva Lev-Ari, PhD, RN, as evidenced by
https://pharmaceuticalintelligence.com/2016/07/21/key-opinion-leader-kol-aviva-lev-ari-phd-rn-as-evidenced-by/
3.3 Medical Education Development: content creation in five specialties in medicine and life sciences
The Voice of Prof. Marc Feldman
https://profiles.stanford.edu/marcus-feldman
“Dr. Lev-Ari founded the LPBI Group (Leaders in Pharmaceutical Business Intelligence Group) in 2012 as a start-up dedicated to electronic publishing in the biomedical sciences. She continues as editor-in-chief of LPBI’s open access scientific journals. After a twenty-year career as an executive in research and technology, she re-invented herself and devoted her life to health care. She studied biological science at Northeastern University, then nursing and became a registered nurse in 2008. She was involved in cardiovascular research through pharmacological therapy while studying at Northeastern, during which she developed her skills at recognizing valuable and innovative research. She worked in long-term post-acute episode nursing management, which enabled her to see health care from the patient’s perspective. The clinical perspective dominates the Journal’s articles.
https://pharmaceuticalintelligence.com/about/
Site statistics on 7/15/2018:
1,455,239 e-Readers,
- 2,348 subscribers,
- 5,355 Scientific Articles,
- 7,300 comments by scientists
Under Dr. Lev-Ari’s direction, 5,318 articles that review biomedical research in an advanced curatorial style have been published with over 1,435,270 eReaders. In her active role as editor-in-chief, she has curated or co-curated 557 articles that make biomedical research advances available online to medical students and health-care professionals, as well as graduate students in the biomedical sciences, and the interested public. These 557 articles are included in 13 Volumes of a 16-Volume BioMed e-Series, all found on Amazon.com’s shelves in Medicine and Life Sciences. She has assembled an impressive and highly motivated group of authors. In addition, the articles have stimulated a great deal of interesting responses that are also available online to the readers of the books and articles published online by LPBI Group.
Dr. Lev-Ari has overseen and contributed many articles to the thirteen volumes in medicine and life sciences that LPBI has published as electronic books (e-books). The books include medical science, diagnostics, and therapy. Their sustainability is maintained by:
- Online continuing updates are made to articles in the journal.
- Each e-book has an abbreviated electronic table of contents which consists of live links for each article in an e-book to the article in the journal. Readers of the e-books click on the link and get the most updated “State of Science” for each topic in the e-books.
- “Journal Ontology” is a relational and hierarchical knowledge base allowing for expansion of the content creation process on these two dimensions and but not limited to these two. For example: One of the research categories “Interviews with Scientific Leaders”, includes in its growth plan the option of podcasts, an audio media component that will supplement the video media component, which is used extensively in the BioMed e-series.
Dr. Lev-Ari’s work has a future-oriented vision. The 5,318 articles she has directed constitute an “Intellectual Property Vault”, which: has the potential of being used for creation of new titles for new e-books. It is a reservoir of Ideas in the form of research categories populated by scientific curations.
- Online reach is growing and is driven by cutting edge subject matters added on a continuing basis to the Intellectual Property Vault.
- “Innovations in Drug Discovery” and “Drug Delivery” are covered in real time, on average up to 12 per year, 2013 – 2017
- In 2018, at least ten “International Leading Breakthroughs in BioTechnology Conferences” will be covered in real time by Dr. Lev-Ari.
The material produced by Dr. Lev-Ari is transformative because it makes cutting-edge biomedical research innovation widely available to the non-research community. Her method of curation as scientific communication includes synthesis, analysis, and interpretation. Experts, authors, writers add their depth in thinking on subjects to the breath of materials selected by their expertise to form new curations or updating existing ones. The books are transformative in their capacity to accelerate diffusion of scientific innovations. The curation is done by experts with a perspective on the field allowing for the creation of the scientific context that unifies conceptual evolution with the breakthrough analyzed in the curation and the future implications to be anticipated.
Dr. Lev-Ari’s work is innovative and creative. It has perfected the art of scientific curation for medical education of the cutting-edge literature. It makes all the curations available through open access and uses attractive titles for all articles: for example, “Identification of Biomarkers that are Related to the Actin Cytoskeleton”. She has created hierarchical ontologies, with the help of medical experts. As examples, the Journal has:
- 960 articles on “Cancer Biology & Innovations in Cancer Therapy”,
- 739 articles on “Frontiers in Cardiology and Cardiovascular Disorders”
- 636 articles on “Personalized and Precision Medicine & Genomics Research”
- 595 articles on “Cell Biology and Cell Circuits” that can be accessed at https://pharmaceuticalintelligence.com/.
Below are examples of the effect of Dr. Lev-Ari’s curation as measured by the number of electronic viewers. For all of them, Dr. Lev-Ari was either sole curator or had co-curators.
- “Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)” (11,606 viewers). A Co-curation.
- “Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care” (5,865 viewers). A Co-curation.
- “Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes” (1,919 viewers). Single Author.
- “Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation” (1,059 viewers). Single Author.
- “Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes” (1,339 viewers). Single Author.
- “Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?” (1,472 viewers). Single Author.
- “Treatment of Refractory Hypertension via Percutaneous Renal Denervation” (1,085 viewers). Single Author.
It is remarkable that Dr. Lev-Ari has been successful at so many different endeavors, from academia, business, health care provider, and medical science publisher. She is an example to all Berkeley graduates that growth and productivity begin with graduation and any one of multiple trajectories may culminate in career success.”
-
Mentoring Roles
- Teaching Assistant, Hebrew University. In the last year before graduation all students need to write a scientific paper based on secondary material, class had 24 students. Under my guidance each student developed an outline for the final paper and all graduated on time. I motivated five to continue to the Masters degree following the BA.
- Teaching Assistant, UC Berkeley. Several students reported to me that the quantitative methods course was the one course that taught them hands-on computer access for statistical data analysis and they believed that they were more prepared to get a job with their new mastery of quantitative methods.
- SRI International, guided a team of researchers in computer modeling, pooled cross-sectional time series, paradigms of measurement that were not covered in Masters courses at Yale.
- Amdahl Corporation managed the demand forecasting quarterly efforts for seven cycles. Guided a team of financial analysts MBA level. Our team received the Excellence Award, 10/1989.
- MITRE, Economic and Decision Analysis Center (EDAC) designed the research plan for a 137-professional center in three locations, and mentored groups by project.
- PSC, led the analytics team in development of digital infrastructure for digital marketplace analytics. My mentee, SB, was encouraged to pursue a PhD at UCLA. Since 2018 she has been on the faculty of USC.
- McGraw-Hill’s team thrived and weathered organizational restructuring.
- LPBI Group since 4/2012, built an entire Team of Editors and Experts, Authors, Writers that completed the articles and the book published todate
Our Team
- Aviva Lev-Ari, PhD, RN, Director and Founder
- Members of the Board
- Senior Editors
- Experts, Authors, Writers (EAWs)
- Business Development & Private Equity Investment
- Scientific Delegation Members & Patent Holders
- Inventors: Biologics
- Inventors: Medical Devices
- Research Associates
Selection of Journal’s Chief Scientific Officer (CSO) and BioMed e-Series Content Consultant (CC): Series B, C, D, E
L.H. Bernstein, MD, FCAP
Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
e-Books in Medicine
Amazon’s Aviva Lev-Ari Page
Discover books, read about the author, find related products, and more.15 results for Kindle Store :
“Aviva Lev-Ari”
Pharmacological Agents in Treatment of Cardiovascular Diseases (Series A: Cardiovascular Diseases Book 5)
Dec 23, 2018 | Kindle eBook
by Justin D. Pearlman and Larry H. BernsteinSold by: Amazon Digital Services LLCInterventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment (Series A: Cardiovascular Diseases Book 6)
Dec 24, 2018 | Kindle eBook
by Justin D. Pearlman and Larry H. BernsteinSold by: Amazon Digital Services LLC
The Immune System, Stress Signaling, Infectious Diseases and Therapeutic Implications: VOLUME 2: Infectious Diseases and Therapeutics and VOLUME 3: The … (Series D: BioMedicine & Immunology)
Sep 4, 2017 | Kindle eBook
by Larry H. Bernstein and Aviva Lev-Ari
The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures … E: Patient-Centered Medicine Book 1)
Oct 16, 2017 | Kindle eBook
by Larry H. Bernstein and Aviva Lev-AriSold by: Amazon Digital Services LLC
Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1)
Jun 20, 2013 | Kindle eBook
by Margaret Baker PhD and Tilda Barliya PhDSold by: Amazon Digital Services LLC
Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2)
May 13, 2017 | Kindle eBook
by Larry H. Bernstein and Demet SagSold by: Amazon Digital Services LLC
Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders (Series E)
Dec 9, 2017 | Kindle eBook
by Larry H. Bernstein and Aviva Lev-AriSold by: Amazon Digital Services LLC
Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics
Nov 28, 2015 | Kindle eBook
by Justin D. Pearlman MD ME PhD MA FACC and Stephen J. Williams PhDSold by: Amazon Digital Services LLC
Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1)
Aug 10, 2015 | Kindle eBook
by Larry H Bernstein MD FCAP and Prabodh Kumar Kandala PhDSold by: Amazon Digital Services LLC
Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1)
Jul 21, 2015 | Kindle eBook
by Larry H. Bernstein MD FCAP and Prabodah Kandala PhDSold by: Amazon Digital Services LLC
Medical 3D BioPrinting – The Revolution in Medicine Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices (Series E: Patient-Centered Medicine Book 4)
Dec 30, 2017 | Kindle eBook
by Larry H. Bernstein and Irina RobuSold by: Amazon Digital Services LLC
Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation
Nov 29, 2015 | Kindle eBook
by Larry H. Bernstein MD FCAP and Aviva Lev-Ari PhD RNSold by: Amazon Digital Services LLC
Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3)
Dec 26, 2015 | Kindle eBook
by Larry H. Bernstein MD FACP and Aviva Lev-Ari PhD RNSold by: Amazon Digital Services LLC
Genomics Orientations for Personalized Medicine (Frontiers in Genomics Research Book 1)
Nov 22, 2015 | Kindle eBook
by Sudipta Saha PhD and Ritu Saxena PhDSold by: Amazon Digital Services LLC
Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases
Dec 26, 2015 | Kindle eBook
by Justin D. Pearlman MD ME PhD MA FACC and Ritu Saxena PhD
See collection of links to electronic Table Of Contents for 16 Volumes:
LPBI Group is an early stage start up in three domains:
(1) Knowledge-based Informational Services
Open Access OnLine Scientific Journal The Site Statistics on 9/14/2016: (1,053,618 e-Readers, 2,142 Subscribers, 4,892 Scientific Articles, ~8000 Comments by Scientists)
BioMed e-Series, Five Series in Medicine, 8 e-Books on Amazon.com, 4 e-Books in 2016 and 3 e-Books in 2017
Real Time Press Coverage of BioTech Global Premier Conferences, Portfolio of ~30 events have been covered in the last 3 years. In 2016, Dr. Lev-Ari has launched an
Audio-Podcast Series in Medicine, 5 tracks – Concept phase.
Representation of US Patent Holders for Commercialization, Licensing and Partnerships
(2) Dr. Lev-Ari guides a Team of Scientists in Drug Discovery & Drug Delivery Research
- Drug Discovery with 3D BioPrinting
- Drug Delivery System – One solution for many agents for many indications
(3) As a Key Opinion Leader (KOL) Dr. Lev-Ari and her Team are involved in Business Financial Transactions (No Securities Traded)
· Funding Early Stage Ventures and Businesses, IP Licensing and Business Partnerships for MEDICAL DEVICES, Pharmaceutical Informational PLATFORMS and INVENTIONS IN BIOLOGICS.
The venture operates as an online scientific intellectual EXCHANGE for curation and reporting on frontiers in Biomedical, Biological Sciences, Healthcare Economics, Pharmacology, Pharmaceutical & Medicine. The website, http://pharmaceuticalintelligence.com , is a scientific, medical and business multi expert authoring environment in several domains of LIFE SCIENCES, PHARMACEUTICAL, HEALTHCARE & MEDICINE INDUSTRIES.
http://pharmaceuticalintelligence.com/about/
The Site Statistics on 8/17/2018:
1,470,126 e-Readers,
2,348 Subscribers,
5,368 Scientific Articles,
~8000 Comments by Scientists
http://pharmaceuticalintelligence.com
Links to each article by Aviva Lev-Ari, PhD, RN to be found at
http://pharmaceuticalintelligence.com/?s=Aviva+Lev-Ari%2C+PhD%2C+RN
These articles have been viewed on 8/17/2018, since the first article was published on 4/30/2012, by 373,776 viewers.
Aviva Lev-Ari, PhD, RN curated most of the articles in the research category
Frontiers in Cardiology – 745 articles
http://pharmaceuticalintelligence.com/?s=Frontiers+in+Cardiology
| Author, Curator and
Editor-in-Chief |
On 8/17/2018 e-Readers since 4/30/2012 |
Journal Articles on 8/17/2018 |
|---|---|---|
Aviva Lev-Ari, PhD, RN |
373,776
|
3,160 |
PLEASE SCROLL DOWN!
NOW
This page has the following sub pages.
- Scientific and Medical Affairs Chronological CV
- Technology Executive, Methodology and Decision Scientist, Functional CV
- Contributions to Design of Algorithm-based Decision Support Systems
- Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
- HealthCare Delivery – Long Term Post Acute Care Nursing Management CV
- Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence
- List of Invited Lectures, 1983 -2004
- List of Publications, 1983 – 2004
- List of Publications, 2006 – Present
- Cardiovascular Diseases and Pharmacological Therapy: Curations, 2006 – 4/2018
- MedTech & Medical Devices for Cardiovascular Repair – Curations
- Stem Cells and Cardiac Repair: Content Curation & Scientific Reporting
- Regulatory Affairs: Publications on FDA-related Issues – Aviva Lev-Ari, PhD, RN
- Cancer Research: Curations and Reporting
- Autobiographical Annotations: Tribute to My Professors
- Public Eulogy of Note: Prof. Allan Pred, University of California, Berkeley
- Public Eulogy of Note: Prof. David Hooson, University of California, Berkeley
- Photography and The Arts
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
very interesting article and it is useful for me